CDH1 and neoplasm: Thus, while previous results including pharmacological leads from the isogenic E-cadherin deficient MCF10A model, or from a study in a CDH1 null drosophila model, might be mostly applicable to the early, intramucosal T1a stage, we propose that leads derived from patient-derived c.1380delA CDH1 SB.mhdgc-1 cells capture later tumor stages shifting from a drug profile with primarily chemopreventative merit to a therapeutic one.